Biotechnology
Biopharmaceutical
Pharmaceutical

Fate Therapeutics

$15.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.19 (-1.18%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell FATE and other stocks, options, ETFs, and crypto commission-free!

About

Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Read More Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Employees
104
Headquarters
San Diego, California
Founded
2007
Market Cap
1.04B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
669.26K
High Today
$16.51
Low Today
$15.60
Open Price
$16.09
Volume
249.38K
52 Week High
$19.11
52 Week Low
$8.35

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Cancer Prevention
Therapy
Technology
2013 IPO

News

Simply Wall StMar 11

Should You Be Pleased About The CEO Pay At Fate Therapeutics, Inc.’s (NASDAQ:FATE)

J. Wolchko has been the CEO of Fate Therapeutics, Inc. (NASDAQ:FATE) since 2015. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that the business demonstrates. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to consider the appropriateness of CEO pay levels. See our latest analysis for Fate Therapeutics How Does J. Wolchko’s Compensatio...

180
MarketBeatMar 6

Stock Price, News, & Analysis for Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hemato...

28
The Motley FoolMar 6

Fate Therapeutics Inc (FATE) Q4 2018 Earnings Conference Call Transcript

Fate Therapeutics Inc (NASDAQ:FATE) Q4 2018 Earnings Conference Call , 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the Fate Therapeutics Fourth Quarter 2018 Financial Results Conference Call. At this time, all participants are in listen-only mode. This call is being webcast live on the Investors & Media section of Fate's website at fatetherapeutics.com. As a reminder, today's call is being recorded. I would now like to intro...

91

Earnings

-$0.37
-$0.32
-$0.27
-$0.22
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.